Fluid biomarker-guided monitoring in immunomodulatory Alzheimer's trials

alzheimers proposed composite 64%
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
64%
Novelty
—
Mechanistic
—
Druggability
—
Priority
64%
Importance
64%
Tractability
—
Market price
50%

Description

Peripheral immune stimulation trials lack validated companion biomarkers for real-time CNS target engagement. Need for longitudinal CSF/plasma inflammation endpoints that correlate with clinical outcomes in immunotherapy trials.